JP4359046B2 - Anti-stress agent - Google Patents

Description

【００２７】

【００２８】
表１の結果より、対照群、ユビデカレノンとエゾウコギの抽出物を含まないカプセル内容物を投与した群、及びユビデカレノンと高麗人参の抽出物を含むカプセル内容物を投与した群は、寒冷ストレスの負荷により、体重の増加が著しく抑制されていることが判明した。ユビデカレノンあるいはエゾウコギの抽出物を含むカプセル内容物を投与した群は、上記群と比較し、寒冷ストレスによる体重増加の抑制が、ある程度緩和された。これに対して、ユビデカレノンとエゾウコギの抽出物を含むカプセル内容物を投与した群は、常温で飼育した対照群と同程度の体重増加が認められ、寒冷ストレスによる体重増加の抑制が、著しく緩和されていることが判明した。
【００２９】
表２の結果より、対照群、ユビデカレノンとエゾウコギの抽出物を含まないカプセル内容物を投与した群は、寒冷ストレスの負荷により、血中コルチコステロン濃度が上昇し、脾及び胸腺の重量が減少していることが判明した。ユビデカレノンあるいはエゾウコギの抽出物を含むカプセル内容物を投与した群、及びユビデカレノンと高麗人参の抽出物を含むカプセル内容物を投与した群は、上記群と比較して、血中コルチコステロン濃度の上昇抑制、並びに脾及び胸腺の重量減少の抑制が認められた。これに対して、ユビデカレノンとエゾウコギの抽出物を含むカプセル内容物を投与した群の血中コルチコステロン濃度、並びに脾及び胸腺の重量は、常温で飼育した対照群と同程度であり、著しい抗ストレス効果が発揮されていることが明らかとなった。
【００３０】
実施例２、３及び４についても、寒冷ストレス試験を実施したところ、実験例１と同様に、優れた抗ストレス作用が認められた。
【００３１】
以上の結果より、本発明に係るユビデカレノンとエゾウコギの抽出物を含有する抗ストレス剤は、ユビデカレノンあるいはエゾウコギの抽出物を単独で用いたもの、あるいはユビデカレノンと高麗人参の抽出物を含有するものより、はるかに優れた抗ストレス作用を有することが明らかとなった。BACKGROUND OF THE INVENTION
[0001]
The present invention relates to an anti-stress agent. More specifically, the present invention relates to an anti-stress agent characterized by containing an extract of ubidecarenone and Ezoukogi.
[Prior art]
[0002]
Modern society is in an environment where science and technology are becoming more sophisticated and complex, and the social situation is turbulent, and people are exposed to various stresses. In particular, in an internationalized society, complicated human relationships are formed, and various symptoms caused by mental stress have been reported.
[0003]
Conventionally, chemical synthesis agents such as tranquilizers, anti-anxiety agents, and sleeping pills have been used as agents for reducing and preventing mental and physical symptoms caused by stress. However, these drugs have problems of habituation and side effects and are not preferred for daily use. Therefore, there is a demand for an anti-stress agent that can be used on a daily basis and exhibits a safe and sufficient effect.
[0004]
Ubidecarenone has been used for many years as a treatment for congestive heart failure to improve myocardial infarction, hypertension, motivation, shortness of breath, etc., and is known as a safe pharmaceutical with very few side effects (see Non-Patent Document 1). ). Other therapeutic agents include ubiquinone synonymous with ubidecarenone and a tonic containing nourishing tonic (see Patent Document 1), ubidecarenone, a dementia treatment containing vitamin B6 and iron as active ingredients (see Patent Document 2). Although sleep apnea treatment drugs (see Patent Document 3) and the like are known, there are no examples of use as antistress agents.
[0005]
On the other hand, Ezocogi is known to have an anti-fatigue action, an anti-stress action, an action to improve immune function, etc. (see Non-Patent Document 2). As an anti-stress action, a therapeutic or preventive agent for stress gastric ulcer containing an extract of Ezo-kogi as an active ingredient (see Patent Document 4), a composition for oral administration having an anti-stress effect comprising Ezo-kogi, trash and eucommia ( However, there is no example of an anti-stress agent combining an extract of ubidecarenone and Ezoukogi.
[0006]
[Patent Document 1]
JP 7-278002 A [Patent Document 2]
Japanese Patent Laid-Open No. 4-49235 [Patent Document 3]
JP-A-2-188523 [Patent Document 4]
JP 2002-3391 A [Patent Document 5]
Japanese Patent Laid-Open No. 9-227394 [Non-Patent Document 1]
“Food style 21” by Jun Funahashi, Food Chemistry Newspaper, July 2002, p. 66-71
[Non-Patent Document 2]
“Functional research of medicinal herbs”, published on October 8, 1999, p. 38-43
[Problems to be solved by the invention]
[0007]
An object of the present invention is to provide an anti-stress agent which has an anti-stress action and is safe even when taken for a long period of time.
[Means for Solving the Problems]
[0008]
As a result of diligent research on the above problems, the present inventors have found that a combination of an extract of ubidecarenone and Ezoukogi has an extremely excellent antistress effect, and have completed the present invention. That is, this invention relates to the anti-stress agent characterized by containing the extract of ubidecarenone and Ezoukogi.
[0009]
The ubidecalenone according to the present invention is also called ubiquinone or coenzyme Q10, and is a coenzyme related to succinate dehydrogenase activity, assists the function of the electron transport system in mitochondria, and is deeply involved in the synthesis of ATP. Are known. The ubidecalenone according to the present invention can be used with a commercially available content of 98% or more, and a commercially available 4% -containing emulsion type can be used for beverages and the like.
[0010]
Ezoukogi (Acanthopanax senticosus Harms) according to the present invention is a plant belonging to the family Uridaceae inhabiting the northeastern part of Russia, China, and Japan, and is also referred to as “Hariukogi”, “Siberian ginseng” and “Eletrocox”. The root of the elephant of the present invention can be any part of the root, stem, branch or leaf of the elephant, but the root is particularly preferred. As the solvent used in the production of the extract of Ezoukogi according to the present invention, water, alcohol, acetone, propylene glycol, 1,3-butylene glycol, or a mixed solvent thereof can be appropriately used as necessary. Moreover, the said extract can be used with any forms, such as an extract, a concentrated liquid, or a dry powder.
[0011]
Ezoukogi belongs to the same sorghum family as Ginseng (scientific name: Panax ginseng CA Meyer), but the active ingredient is greatly different. The active ingredient of Ekokogi is a lignan compound, while ginseng is a saponin compound. Ezoukogi, also called Siberian ginseng, is a completely different plant because it has a different genus and different active ingredients from ginseng.
[0012]
The intake of the extract of ubidecarenone and Ezoukogi according to the present invention varies depending on the form, symptoms, age, weight, etc., but ubidecalenone is 1 to 500 mg / day, preferably 5 to 200 mg / day, more preferably 10 to 100 mg / day. Day. The intake of the extract of Ezoukogi is 1 to 20000 mg / day, preferably 10 to 10000 mg / day, more preferably 50 to 4000 mg / day in terms of dry matter of Ezoukogi.
[0013]
The form of the antistress agent according to the present invention is not particularly limited. For example, capsules, tablets, granules, powders, beverages, gums, chocolates, strawberries, noodles, breads, cakes, biscuits, canned foods, retort foods, livestock meat products, marine products, margarine, butter, mayonnaise, etc. Pharmaceutical and food forms can be employed. Of these, capsules, tablets, granules, beverages and the like that allow easy adjustment of the intake are preferred.
[0014]
The antistress agent according to the present invention includes, in addition to herbal medicines, vitamins, minerals, amino acids, etc., excipients such as lactose, starch, cellulose, maltitol, dextrin, glycerin fatty acid esters, etc. , Surfactants such as sucrose fatty acid esters, coating agents such as gelatin, pullulan, shellac, zein, fats and oils such as wheat germ oil, rice germ oil, safflower oil, waxes such as beeswax, rice bran wax, carnauba wax, Sweeteners such as sucrose, glucose, fructose, stevia, saccharin, and sucralose, and acidulants such as citric acid, malic acid, and gluconic acid can be appropriately blended. Herbal medicines include ginseng, American ginseng, ginseng, ganoderma, propolis, agaricus, blueberries, ginkgo leaves and extracts thereof. Examples of vitamins include oil-soluble vitamins such as vitamins A, D, E, and K, and water-soluble vitamins such as vitamins B1, B2, B6, and B12, niacin, pantothenic acid, folic acid, and biotin.
[0015]
【Example】
EXAMPLES Hereinafter, although an Example demonstrates this invention still in detail, this invention is not restrict | limited to the said Example at all. The numbers in parentheses at the end of the extract of Ezoukogi represent the weight ratio of the dried product of the raw Ezokogi to the obtained extract. For example, when 1 g of an extract is obtained from 5 g of dried Ezogigi, it is indicated as (5: 1).
[0016]
Example 1 Capsule <Prescription> Compounding amount (%)
1. Ubidecarenone 4.0
2. Hot water extract of Ekokogi (10: 1) 20.0
3. Corn starch 73.0
4). Sucrose fatty acid ester 3.0
<Production method>
Ingredients 1-4 are mixed and 250 mg is filled into No. 2 hard capsule to obtain a capsule. By taking 3 capsules per day, the capsule can be ingested at 30 mg / day for ubidecarenone and 1500 mg / day for the extract of Ekokogi as a dried product of Ezocogi.
[0017]
COMPARATIVE EXAMPLE 1 Comparative Example 1 was obtained by replacing the hot water extract of Ubidecarenone and Ezoukogi with corn starch in Example 1 capsules containing no extract of Ubidecarenone and Ezoukogi.
[0018]
Comparative Example 2 Comparative Example 2 was obtained by replacing Ubidecarenone with cornstarch in Capsule Example 1 containing no ubidecarenone.
[0019]
Comparative Example 3 Capsules containing no extract of Ezokogi In Comparative Example 3, the hot water extract of Ekokogi was replaced with corn starch.
[0020]
Comparative Example 4 Capsule with ginseng extract blend Comparative Example 4 was obtained by replacing the hot water extract of ginseng with a ginseng extract in Example 1.
[0021]
Example 2 Tablet <Prescription> Formulation amount (%)
1. Ubidecarenone 8.0
2. Hot water extract of Ekokogi (20: 1) 20.0
3. Lactose 50.0
4). Reduced maltose starch syrup 19.0
5. Sucrose fatty acid ester 3.0
<Production method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 5 is added and tableted to give a 300 mg tablet. By ingesting 3 tablets per day, ubidecalenone can be ingested at 72 mg / day, and the extract of Ezoukogi can be ingested as 3600 mg / day as a dried product of Ezocogi.
[0022]
Example 3 Granule <Prescription> Compounding amount (%)
1. Ubidecarenone 10.0
2. 10% ethanol extract of Ekokogi (5: 1) 50.0
3. Reduced maltose starch syrup 25.0
4). Cellulose 15.0
<Production method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. The granule can be ingested at a dose of 1 g at a time twice a day, so that ubidecarenone can be ingested at a dose of 200 mg / day, and the extract of Ekokogi can be ingested at a dose of 5000 mg / day.
[0023]
Example 4 Beverage <Prescription> Ubidecarenone (4% emulsification type) 5.0 g
2. 30% ethanol extract of Ekokogi (1: 1) 1.0 g
3. Sucrose 60.0 g
4). Citric acid 7.0 g
5. Perfume appropriate amount 6. Bring the total volume to 1000 with purified water.
<Production method>
Add ingredients 1 to 5 to ingredient 6, stir and dissolve, filter, heat sterilize to 1000 mL, and fill this into a 50 mL glass bottle. The beverage can be ingested once a day for 10 mg / day of ubidecarenone and 50 mg / day of the extract of Ezoukogi as a dried product of Ezocogi.
[0024]
【The invention's effect】
The present invention can provide an excellent anti-stress agent. The effects of the present invention will be described in the following experimental examples.
[0025]
Experimental example 1
Forty-two ICR mice (male, Nippon SLC Co., Ltd.) were divided into 7 groups, each with 6 mice. The control group 2 was administered with distilled water only, the first group was Example 1, the second group was Comparative Example 1, the third group was Comparative Example 2, the fourth group was Comparative Example 3, the In 5 groups, the capsule contents of Comparative Example 4 were suspended in distilled water at 10 mg / kg / day, and were orally administered once a day for 4 consecutive days. Next, control group 1 and 6 mice of groups 1-5 were given 4 hours on day 4 of sample administration, 7 hours on day 5, 24 hours on days 6 and 7, a 5 ° C. cold room. Was bred and given cold stress. One of the remaining control groups was raised at room temperature as a normal control group. After 4 days of stress loading, the body weight was measured, and the weight before and after stress loading and the weight difference were shown in Table 1. In addition, blood corticosterone concentration, which is known to increase due to stress, was measured. Further, necropsy was performed to measure the weight of spleen and thymus known to atrophy with stress. Table 2 shows the results of measurement of blood corticosterone concentration and the results of weight measurement of spleen and thymus.
[0026]

[0027]

[0028]
From the results of Table 1, the control group, the group administered with capsule contents not containing the extract of ubidecalenone and Ezoukogi, and the group administered with capsule contents containing the extract of ubidecarenone and ginseng were subjected to cold stress. It was found that weight gain was significantly suppressed. In the group to which capsule contents containing an extract of ubidecarenone or Ezoukogi were administered, the suppression of weight gain due to cold stress was moderated to some extent as compared to the above group. In contrast, the group administered capsule contents containing the extract of ubidecarenone and Ezoukogi showed the same weight gain as the control group bred at room temperature, and the suppression of weight gain due to cold stress was remarkably alleviated. Turned out to be.
[0029]
From the results in Table 2, the control group, the group administered with capsule contents not containing the extract of ubidecarenone and Ezoukogi, increased blood corticosterone concentration due to cold stress and decreased the weight of spleen and thymus Turned out to be. Increased blood corticosterone concentration in the group administered capsule content containing ubidecarenone or Ezoukogi extract and in the group administered capsule content containing ubidecalenone and ginseng extract compared to the above group Suppression and suppression of spleen and thymus weight loss were observed. In contrast, the blood corticosterone concentration and the weight of the spleen and thymus in the group administered with the capsule contents containing the extract of ubidecarenone and Ezoukogi were similar to the control group bred at room temperature, which is a significant It became clear that the stress effect was exhibited.
[0030]
As for Examples 2, 3 and 4, when the cold stress test was performed, an excellent antistress action was observed as in Experimental Example 1.
[0031]
From the above results, the anti-stress agent containing the extract of ubidecarenone and Ezoukogi according to the present invention is the one using the extract of ubidecarenone or Ezoukogi alone, or the one containing the extract of ubidecarenone and ginseng, It became clear that it had a much superior anti-stress action.

Claims (2)

The antistress agent characterized by containing the extract of ubidecarenone and Ezoukogi. The antistress agent according to claim 1, which is in a form capable of ingesting 1 to 20000 mg / day of ubidecarenone in an amount of 1 to 500 mg / day and an extract of Ezoukogi converted to a dried product of Ezoukogi.